Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine

Gynecological Endocrinology

Volumn 20, Issue 6, 2005, Pages 317-321

  Adler, Ildikó ^a   Barsi, Péter ^b   Czirják, Sándor ^c   Varga, Ibolya ^a   Gergics, Péter ^a   Jakab, Csilla ^a   Rácz, Károly ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^c NATIONAL INSTITUTE OF NEUROSURGERY   (Hungary)

Author keywords

Bromocriptine; Macroprolactinoma; Tumor enlargement; Tumor shrinkage

Indexed keywords

BROMOCRIPTINE; PROLACTIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; DRUG RESPONSE; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTINOMA; SECONDARY AMENORRHEA; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME; VISUAL FIELD DEFECT;

ADULT; BROMOCRIPTINE; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HORMONE ANTAGONISTS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA;

EID: 22144466569     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500098034     Document Type: Article

References (22)

1. Thorner MO, Martin WH, Rogol AD, Morris JL, Perryman RL, Conway BP, Howards SS, Wolfman MG, MacLeod RM. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 1980;51:438-45.
2. Kleinberg DL. Medical treatment of pituitary tumors. Semin Reprod Endocr 1984;2:63-72.
3. Besser GM, Wass JAH, Grossman A, Ross R, Doniach I, Jones AE, Rees LH. Clinical and therapeutic aspects of hyperprolactinemia. In: Macleod RM, Thorner MO, Scapagnini U, editors. Prolactin. Basic and clinical correlates. Padova: Liviana Press; 1984. pp. 833-847.
4. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G. Low doses of dopamine agonists in the long term treatment of macroprolactinomas. N Engl J Med 1985;313:656-659.
5. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-240.
6. Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994;8:175-181.
7. Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997;82:996-1000.
8. Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B, Lombardi G. New medical approaches in pituitary adenomas. Horm Res 2000;53(Suppl 3):76-87.
9. Kovacs K, Stefaneanu L, Horvath E. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. J Neurosurg 1995;82:886-890.
10. Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454-456.
11. Cannavo S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 1999;22:306-309.
12. Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery 1989;24:417-423.
13. Dallabonzana D, Spelta B, Oppizzi G, Tonon C, Luccarelli G, Chiodini PG, Liuzzi A. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J Endocrinol Invest 1983;6:47-50.
14. Breidahl HD, Topliss DJ, Pike JW. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br Med J Clin Res Ed 1983;287:451-452.
15. Lopez-Espinoza E, Ayala AR, Grimaldo J, Kunhardt J, Villaneuva C. Macroprolactinoma resistant to bromocriptine. Arch Invest Med 1989;20:1-8.
16. Saeki N, Nakamura M, Sunami K, Yamaura A. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 1998;45:529-537.
17. Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 1998;49:250-253.
18. Peillon F, Bression D, LeDafniet M, Brandi AM, Li J, Pagesy P, Birman P, Blumberg-Tich J, Michard M, Kujas M, Landolt AM, Heitz PU, Zapf J, Girard J, Del Pozo E. 1988. Receptor studies in human pituitary adenomas. Do they contribute to a better understanding of their pathogenesis? In: Landolt AM, et al., editors. Advances in pituitary adenoma research. Oxford: Pergamon Press. pp. 67-76.
19. Chanis BS, Check JH. Relative resistance of a macroprolactinoma to bromocriptine therapy during pregnancy. Gynecol Endocrinol 1996;10:91-94.
20. Garcia MM, Kapcala LP. Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 1995;18:450-455.
21. Di Sarno A, Landl ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000;53:53-60.
22. Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma. Clin Endocrinol (Oxf) 1995;43:49-53.